- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ashfield Healthcare Communications Expands Footprint with Argon Global Healthcare Network Alliance
The UK’s Ashfield Healthcare Communications and Argon Global Healthcare Network have announced that they have combined their capabilities to assist clients with managing their brands in existing locations and expanding into new.
“The complementary service offerings and greater geographical reach from Ashfield and Argon will provide clients a non-holding company approach to the global environment. Collectively this partnership provides our clients with unprecedented agility and access to a full breadth of communications services tailored with a deep understanding of cultural and business nuances for their regional and local needs,” a press release reports.
Ashfield Healthcare Communications president Doug Burcin commented: “I am delighted with this partnership in that it continues to deliver on our approach to being a truly global micro network. We have a well-established presence in the UK, Germany, Japan and US for delivering our solutions at the intersection of science, data and creativity so we are excited to come together with the Argon Global Healthcare Network to be able to deliver this on an even more global scale.”
Doug Burcin
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
